Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Fractyl Health, Inc. (GUTS – Research Report) and keeping the price target at $10.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Michael Ulz has given his Buy rating due to a combination of factors that highlight Fractyl Health, Inc.’s promising progress in its clinical programs. The company’s Revita program is advancing well, with the midpoint analysis of the REMAIN-1 study expected in the third quarter of 2025. This study is crucial as it focuses on weight loss maintenance, and all subjects have achieved significant weight loss in the preliminary phase. Additionally, the pivotal cohort of the study completed enrollment ahead of schedule, indicating strong momentum in their research efforts.
Furthermore, Fractyl Health is making strides with its Rejuva program, an AAV-based gene therapy aimed at treating type 2 diabetes and obesity. The company plans to submit the first CTA module by mid-2025, with initial data anticipated in 2026. These developments, alongside the company’s solid financial position with $42.1 million in cash, provide a robust foundation for future growth, supporting Ulz’s optimistic outlook and Buy rating.